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Background. The deregulated tumorigenic long non-coding RNA (lncRNA) has been reported in several malignancies. However,
there is still no comprehensive study on tongue squamous cell carcinoma (SCC).Methods. Functional reannotation for the human
lncRNA was carried out by ncFANs. Real-time quantitative PCR was used to validate the identified lncRNAs. Results. Using the
functional annotation algorithm from ncFANs, 8 differentially expressed lncRNAs were identified. Lnc-PPP2R4-5, lnc-SPRR2D-1,
lnc-MAN1A2-1, lnc-FAM46A-1, lnc-MBL2-4:1, and lnc-MBL2-4:3 were upregulated in the microdissected tongue SCC tissues. In
comparison, lnc-AL355149.1-1 and lnc-STXBP5-1 showed significant downregulation. High level of lnc-MBL2-4:3 was significantly
associated with the node positive tongue SCC patients. Further, patients with advanced T-stage demonstrated a further reduction
of lnc-AL355149.1-1 in the tumor tissues. Treatment of tongue SCC cells with 5-fluorouracil and paclitaxel can reserve the expression
patterns observed in the tongue SCC tissues. Further, changes of lnc-MBL2-4:3 and lnc-AL355149.1-1 expression levels were noticed
in the cisplatin-resistant tongue SCC cells.Conclusions.Our results demonstrated that functional reannotation allows us to identify
novel lncRNAs using the existing gene expression array dataset. The association of lncRNA with the T-stage and nodal status of
tongue SCC patients suggested that lncRNA deregulation was involved in the pathogenesis of tongue SCC.
1. Introduction
Tongue squamous cell carcinoma (SCC) is a common epithe-
lial cancer identified in the oral cavity. In USA, tongue is the
most common site of oropharyngeal cancer (in comparison
with mouth, pharynx, and others in oral cavity) and the
major histological form is squamous cell carcinoma [1].Major
causative factors included tobacco consumption and alcohol
abuse. Viral infection including human papilloma virus and
Epstein-Barr virus infection might also play a part in the
development of tongue SCC [2]. Tongue SCC is an aggressive
tumor with rapid growth rate and high chance of regional
and distant metastasis. Tumor dimension and the existence
of extracapsular spread (ECS) are predictors of survival [3].
In addition, regional spreading to the cervical lymph node
and distant metastasis of tongue SCC are indicators of poor
prognosis [4, 5].
Different from the mRNA transcript, the codon on the
long non-coding RNA (lncRNA) do not code for any peptides
or proteins. lncRNA refers to RNA molecules with size
over 200 b.p. long and without protein coding functions.
To date, the precise control mechanisms of lncRNA are
not completely understood. LncRNA could be transcribed
by RNA polymerases I, II, and III [6]. LncRNA functions
as epigenetic regulators in the somatic cells and is directly
involved in cell cycle regulation and cell differentiation [7].
Although the precise regulatory mechanism of lncRNA is
not fully understood, evidence suggested that expression of
certain lncRNA is beingmodulated by external stimulus, such
as cellular irradiation and chemotherapeutic agents treatment
[7, 8]. Further, lncRNA is alleged to be involved in the
development of resistant phenotype and deters the efficacy of
cancer treatment [9].
To the best of our knowledge, comprehensive lncRNA
study aiming at identifying novel lncRNA signature has not
yet been carried out in the tongue squamous cell carcinoma.
Hence, in the present study, we aimed at identifying the
candidate lncRNA associated with tongue SCC using the
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Table 1: Primer and probe sequences for qPCR.
Vega ID LNCipedia ID Forward primer (5󸀠-3󸀠) Reverse primer (5󸀠-3󸀠) UPL number∗
OTTHUMG00000020778 lnc-PPP2R4-5 tggattttcatgcctgctg ggctgcattaccagaaaggt 3
OTTHUMG00000012449 lnc-SPRR2D-1 gcctctcctgcaagtgtga tcctcatttatgacattttcagtctc 5
OTTHUMG00000012147 lnc-MAN1A2-1 gagaccgaggaatcttgctg ctcagtgggctcagtaatgct 21
OTTHUMG00000015099 lnc-FAM46A-1 aggggtctcttgtccttggt atcctcttattggcacactgc 26
OTTHUMT00000048111 lnc-MBL2-4:1 gcagccctggagagtttatct cagcataatatggatgtttgaagg 67
OTTHUMT00000048112 lnc-MBL2-4:3 gagccagcaaaggagactga cccagaaggggctcttactc 36
OTTHUMG00000002490 lnc-AL355149.1-1 gaaaactaggcgtctgggaac caaacaatgggagcaagtcc 25
OTTHUMG00000015764 lnc-STXBP5-1 gctatgggaattatttttcctgtg ggtaagccagttttcccttttt 16
∗Probe number in the universal probe library.
microarray dataset available in the public microarray data
repository. Real-time quantitative PCR was then used to
confirm the expression and validate the results in the primary
tongue SCC tissues and the paired normal epithelia. We
also correlated the expression patterns with the clinical
characteristics of tongue SCC patients in order to reveal any
potential clinical use of the lncRNA.
2. Materials and Methods
2.1. Microarray and Functional Reannotation. Microarray
data setGSE9844 containing 38microarray data (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9844/) was ob-
tained from Gene Expression Omnibus (GEO). The dataset
contains 26 microdissected tongue squamous cell carcinoma
tissues and 12 control tissues examined with HumanGenome
U133 (HG-U133) Plus 2.0 array (Affymetrix).
2.2. Functional Reannotation. The probes on the HG-U133
Plus 2.0 array were reannotated for human lncRNA using
non-coding RNA function annotation server (ncFANs) as
described [10]. Differential expressed lncRNAs were selected
using Student’s t-test. A 𝑃 value below 0.05 was considered as
differentially expressed lncRNAs. The 𝑃 value of differential
expression was adjusted with the Benjamini and Hochberg
correction for multiple comparisons.
2.3. Patient Samples. Tongue SCC patients were recruited
at Department of Surgery, The University of Hong Kong,
Queen Mary Hospital, Hong Kong. Written consent of tissue
donation for research purposes was obtained from patients
before tissue collection. The protocol was approved by the
IRB of the hospital (IRB reference number UW 12-123).
Paired tumor and normal tissues (𝑛 = 32) were collected.
Histological confirmation of the tissues was performed by
hospital’s pathologists.
2.4. Real-Time Quantitative PCR. Total RNA was extracted
and purified from the frozen tissues using TRIzol reagent
(Invitrogen). The quality and quantity of the isolated
RNA were examined with Nanodrop. Reverse transcrip-
tion was carried out using cDNA conversion kit (Invitro-
gen). Primers for lncRNA detection and quantification were
designed at Universal ProbeLibrary Assay Design Center
(http://www.roche-applied-science.com/). The LNA-labeled
probe was obtained from the Universal Probe Library (Roche
Applied Science). The lncRNA transcript levels were mea-
sured by LightCycler 480 (Roche Applied Science) and
normalized with the GAPDH levels using 2−ΔCt algorithm.
Primer and probe sequences were listed in Table 1.
2.5. Cell Culture and Drug Treatment. Tongue SCC cell line
HN21B was cultured in RPMI 1640 medium supplied with
10% fetal bovine serum (Gibco), 200Unit/mL penicillin G
sodium (Gibco), 200 𝜇g/mL streptomycin Sulfate (Gibco),
and 0.5 𝜇g/mL amphotericin B (Gibco). The cell line was
incubated in humidified incubator with 5% CO
2
at 37∘C. 5-
Fluorouracil (5-Fu) and paclitaxel were obtained from sigma.
Stock solutions were prepared by dissolving the drugs in
dimethyl sulfoxide (DMSO) at the concentration of 100mM
and 1.2mM respectively. Cisplatin (Sigma) was dissolved
in distilled water at a concentration of 3.3mM. The stock
solutions were freshly diluted to appropriate concentrations
in RPMI 1640 medium before treatment. HN21B cells were
treated by 0–10 𝜇M 5-Fu, 0–8 nM paclitaxel, or 0–64𝜇M
cisplatin for 72 hours followed by in vitro toxicity test. The
toxicity test was performed using the Toxicology Assay Kit
Sulforhodamine B (SRB) assay (Sigma-Aldrich) according
to manufacturer’s manual. The inhibitory concentration (IC)
was calculated from the dose-response curve of HN21B upon
drug treatment.
2.6. Development of Cisplatin-Resistant HN21B Cell Line.
The cisplatin-resistant HN21B cell line was developed by
chronic cisplatin treatment. HN21B cells were exposed to
cisplatin for 3 days, followed by growth recovery in drug-
free medium.The concentration of cisplatin was increased in
the subsequent cycle and the procedure was repeated until
resistance was achieved in HN21B cells.
2.7. Immunocytochemistry. HN21B cells were seeded on glass
slides and fixed with 4% paraformaldehyde. The nucleus was
stained by blue-fluorescent 4󸀠,6-diamidino-2-phenylindole
(DAPI) (Invitrogen); F-actin was labeled in red with Alexa
Fluor 635 phalloidin (Invitrogen).
2.8. Statistical Analysis. Statistical analysis was performed
using SPSS V16.0 (SPSS, Chicago, IL). The statistical dif-
ference between tongue SCC and paired normal epithelia
BioMed Research International 3
4 × 102
2 × 102
1 × 102
8 × 101
6 × 101
4 × 101
2 × 101
0 0
0.0
0.0
0
Re
lat
iv
e e
xp
re
ss
io
n 
of
O
TT
H
U
M
G
0
0
0
0
0
0
2
0
7
7
8
Re
lat
iv
e e
xp
re
ss
io
n 
of
O
TT
H
U
M
G
0
0
0
0
0
0
0
2
4
9
0
Re
lat
iv
e e
xp
re
ss
io
n 
of
O
TT
H
U
M
G
0
0
0
0
0
0
1
5
76
4
Tumor Normal
Tumor Normal Tumor Normal
8 × 103
6 × 101
4 × 101
4 × 103
2 × 101
Re
lat
iv
e e
xp
re
ss
io
n 
of
O
TT
H
U
M
G
0
0
0
0
0
0
1
2
4
4
9
Tumor Normal
4 × 102
2 × 101
3 × 101
1 × 101
2 × 102
Re
lat
iv
e e
xp
re
ss
io
n 
of
O
TT
H
U
M
G
0
0
0
0
0
0
4
8
1
1
2
Tumor Normal
P = 0.035
P = 0.005 P = 0.082
P = 0.004 p < 0.001
4 × 103
2 × 103
2.5 × 102
2.0 × 102
1.5 × 102
1.0 × 102
5.0 × 101
2 × 103
1 × 103
2.0 × 102
1.5 × 102
1.0 × 102
5.0 × 101
Figure 1: Relative expression levels of lncRNAs in paired tumor and normal tissue samples from patients with tongue SCC. The relative
expression levels were normalized toGAPDH by qPCR analysis and the data are displayed as 2−ΔCt.The difference between tumor and normal
was calculated using the Wilcoxon signed-rank test.
was examined using Wilcoxon signed-rank test. All the tests
were two-sided. 𝑃 value <0.05 was considered as statistically
significant.
3. Results
3.1. Differential Expressed lncRNA in Tongue Squamous Cell
Carcinoma. Using the functional annotation algorithm from
ncFANs, 8 differentially expressed lncRNAs were identified
(Table 2). Of the 8 lncRNA, lnc-PPP2R4-5, lnc-SPRR2D-
1, lnc-MAN1A2-1, lnc-FAM46A-1, lnc-MBL2-4:1, and lnc-
MBL2-4:3 were upregulated in the microdissected tongue
SCC tissues. In comparison, lnc-AL355149.1-1 and lnc-
STXBP5-1 showed significant downregulation in the tongue
SCC.
3.2. Validation of lncRNA by Real-Time Quantitative PCR. Of
the 8 lncRNAs, lnc-MAN1A2-1 (OTTHUMG00000012147)
was not detectable in all tissue samples. Lnc-MBL2-4:1
(OTTHUMT00000048111) was detectable in 3% (1/32) tumor
tissue samples and was not detectable in all the normal
tissue samples. Lnc-FAM46A-1 (OTTHUMG00000015099)
was detectable in 22% (7/32) of tumor tissue samples and 13%
of (4/32) normal tissue samples.
For the remaining 5 lncRNAs, 3 were found to be signifi-
cantly upregulated in the primary tongue SCC tissues. Over-
expression of lnc-SPRR2D-1 (OTTHUMG00000012449) and
lnc-PPP2R4-5 (OTTHUMG00000020778) was found in the
tongue SCC tissue (𝑃 = 0.004 & 0.035 resp., Wilcoxon
signed-rank test). Overexpression of the lnc-MBL2-4:3
(OTTHUMT00000048112) in the tongue SCC was highly
significant in comparison with the paired normal epithelia
(𝑃 < 0.001, Wilcoxon Signed Ranked test). Lnc-AL355149.1-
1 (OTTHUMG00000002490) was the only lncRNA found
to be downregulated in the tongue SCC tissues (𝑃 =
0.005, Wilcoxon signed-rank test). The fold-change patterns
(upregulated/downregulated) in the tongue tissues matched
the fold-change patterns in the microarray dataset (Figure 1).
3.3. Correlations with Clinicopathological Parameters of
Tongue SCC Patients. The expression levels of the 4 differ-
entially expressed lncRNAs were correlated with the clinical
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Table 3: Association of lncRNA expression levels with the clinicopathological variables in patients with tongue SCC.
OTTHUMG00000020778 OTTHUMG00000012449 OTTHUMT00000048112 OTTHUMG00000002490
Gender
Male 18 0.866 0.206 0.338 0.099
Female 14
Age
<55 16 0.270 0.254 0.809 0.669
>55 16
T-stage
T1-2 15 0.246 0.153 0.766 <0.001∗
T3-4 17
Nodal stage
Negative 18 0.925 0.065 0.002∗ 0.145
Positive 14
Smoker
Yes 17 0.766 0.628 0.295 0.526
No 15
Drinker
Yes 12 0.552 0.477 0.387 0.387
No 20
∗P value below 0.05 was considered as statistical significance.
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Figure 2: Relative expression levels of lncRNAs in tongue SCC patients with different T-stage (a) and nodal status (b).The relative expression
levels were normalized to GAPDH by qPCR analysis. The difference was calculated using the Mann-Whitney 𝑈 test.
parameters of the patients (Table 3). High level of lnc-MBL2-
4:3 (OTTHUMT00000048112) was significantly associated
with the node positive tongue cancer patients compared to
the node-negative patients (𝑃 = 0.002, Mann-Whitney U
test). Further, lnc-AL355149.1-1 (OTTHUMG00000002490),
the downregulated lncRNA in tongue SCC tissues, displayed
substantial downregulation when the cancer progressed from
early (T1-2) to advanced stages (T3-4). Figure 2 showed the
expression difference of lnc-MBL2-4:3 and lnc-AL355149.1-
1 in the tongue SCC tissues according to the T-stage and
regional nodal status.
3.4. 5-Fu and Paclitaxel Treatment. To explore the potential
functional role of the 2 identified lncRNAs with close
6 BioMed Research International
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Figure 3: Effects of 5-Fu treatment on the expression of lncRNA inHN21B cells. (a) Dose-response curve of HN21B upon 5-Fu treatment. (b)
and (c) Effect of 5-Fu treatment on the expression of OTTHUMG00000002490 and OTTHUMT00000048112, respectively. Bar, SD; 𝑛 = 3;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 by 𝑡-test.
correlation with the clinical features of the tongue SCC
patients, we treated the cancer cell HN21B with 5-Fu
and paclitaxel and examined the subsequent changes
of lnc-MBL2-4 : 3 (OTTHUMT00000048112) and lnc-
AL355149.1-1 (OTTHUMG00000002490) in response to
the drug treatment. We use toxicity test to determine the
inhibitory concentrations of 5-Fu and paclitaxel on tongue
SCC cell line HN21B. For 5-Fu, the IC
10
, IC
30
, and IC
50
were 0.6 𝜇M, 2.2 𝜇M, and 4.3 𝜇M, respectively (Figure 3(a)).
5-Fu treatment enhanced the expression of lnc-AL355149.1-
1 (OTTHUMG00000002490), while it suppressed the
expression of lnc-MBL2-4:3 (OTTHUMT00000048112)
in a dose-dependent manner (Figure 3); for paclitaxel,
the IC
10
, IC
30
, and IC
50
on HN21Bc were 0.1 nM,
1.0 nM, and 2.2 nM, respectively (Figure 4(a)). Similar
to the 5-Fu treatment, the expression of lnc-AL355149.1-1
(OTTHUMG00000002490) was activated upon paclitaxel
treatment (Figure 4(b)). In addition, the expression of
BioMed Research International 7
0
20
40
60
80
100
120
0 2 4 6 8 10
Vi
ab
le
 ce
lls
 (%
)
Concentration of paclitaxel (nM)
(a)
0
0.5
1
1.5
2
2.5
Control IC10 IC30 IC50
Re
lat
iv
e e
xp
re
ss
io
n 
of
  O
TT
H
U
M
G
00
00
00
02
49
0
Concentration of paclitaxel
∗
∗
∗∗
(b)
0
0.2
0.4
0.6
0.8
1
1.2
Control IC10 IC30 IC50
Re
lat
iv
e e
xp
re
ss
io
n 
of
 O
TT
H
U
M
T0
00
00
04
81
12
Concentration of paclitaxel
∗∗
∗∗
(c)
Figure 4: Effects of paclitaxel treatment on the expression of lncRNA in HN21B cells. (a) Dose-response curve of HN21B upon paclitaxel
treatment. (b) and (c) Effect of paclitaxel treatment on the expression ofOTTHUMG00000002490 andOTTHUMT00000048112, respectively.
Bar, SD; 𝑛 = 3; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 by 𝑡-test.
lnc-MBL2-4:3 (OTTHUMT00000048112) was suppressed
under paclitaxel treatment in a dose-dependent manner
(Figure 4(c)).
3.5. Expression Levels ofMBL2-4:3 (OTTHUMT00000048112)
and lnc-AL355149.1-1 (OTTHUMG00000002490) in the
Cisplatin-Resistant HN21B Cells. The cisplatin-resistant
HN21B cells were developed by chronic treatment of HN21B
cells with increasing concentration of cisplatin (Figure 5(a)).
The IC
50
of cisplatin-resistant HN21B was 22.7𝜇M, which
was obviously higher than that of the parental HN21B
cells (7.0 𝜇M). Cisplatin-resistant HN21B cells displayed
spindle-like changes in cell morphology, implicating a more
aggressive phenotype (Figure 5(b)). Further, the cisplatin-
resistant HN21B cells exhibited enhanced expression of
lnc-AL355149.1-1 (OTTHUMG00000002490) and reduced
expression of lnc-MBL2-4:3 (OTTHUMT00000048112) in
comparison with parental HN21B cells (Figure 5).
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Figure 5: Differentially expressed lncRNA in cisplatin-resistant HN21B cells. (a) Dose-response curve of HN21B and cisplatin-resistant
HN21B cells upon cisplatin treatment. (b) Morphology of HN21B and cisplatin-resistant HN21B cells. The nucleus was stained by blue-
fluorescent DAPI; F-actin was labeled in red with Alexa Fluor 635 phalloidin. (c) and (d) Expression of OTTHUMG00000002490 and
OTTHUMT00000048112 in HN21B and cisplatin-resistant HN21B cells. Bar, SD; 𝑛 = 3; ∗∗𝑃 < 0.01 by 𝑡-test.
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4. Discussion
Expression alterations of lncRNA have been reported in
several human tumors. In the past, lncRNA was regarded as
functionless RNA fragment as it carries no protein coding
information. With the characterization of functional non-
coding RNA such as microRNA and PIWI-interacting RNAs
(piRNAs) in the recent years, considerable attention has been
dedicated to identify the active players during the progres-
sion and development of human malignancies. Although
the deregulated lncRNA patterns have been identified in
several cancers, such as prostate and liver cancers, little
is known in oral tongue carcinoma. Using serial analysis
of gene expression (SAGE), lncRNA expression has been
demonstrated in the oral cavity and premalignant oral lesions
located on tongue, gingiva, and buccal mucosa [11]. Recently,
Fang et al. evaluated the expression patterns of lncRNA
UCA1 (urothelial cancer-associated 1) in tongue squamous
cell carcinoma and revealed that high UCA1 expression was
linked to the migratory ability of the epithelial cancer cells
and regional lymph node metastasis [12]. Another example
is lncRNA MEG3 (maternally expressed gene 3). MEG3 is a
lncRNA with the ability to regulate DNA methyltransferase
3B and was found to be downregulated in the tongue SCC
tissues [13]. Low MEG3 level was an independent prognostic
indicator and was associated with poor survival of tongue
SCC patients [13]. The differentially expressed lncRNA could
also be detected in the saliva and was suggested to be a useful
noninvasive biomarker for oral cancer detection [14].
In this study, we used the existing microarray data to
explore the differentially expressed lncRNA patterns in the
tongue SCC tissues. The probesets on the microarray chips
were originally designed to detect the protein-coding genes.
Usually, multiple probes are assigned to individual genes to
cover the entire length of the transcript in order to ensure the
accuracy of measurement. With the advance in our under-
standing of lncRNA and their sequence, it was recognized
that particular probesets on the microarray chips match with
the lncRNA sequence. By reannotation of the microarray
for lncRNA, the expression information of the microarray
dataset could be revealed for subsequent inspection [15]. To
ascertain that the identified lncRNA is deregulated in the
tongue SCC, we carried out real-time quantitative PCR to
validate the expression discrepancy between the epithelial
cancers and normal epithelia of the same patients. One of the
limitations of this study is the sample size of paired tumor and
normal tissue is not big enough. Of the 8 lncRNAs, 4/8 (50%)
were found to be deregulated in our tongue SCC cohort. To
explore the potential role of the lncRNAs in the pathogenesis
of tongue SCC, we correlated the expression levels with
the clinicopathological parameters of tongue SCC patients.
The association of lncRNA with T-stages and regional nodal
status suggested that the lncRNA deregulation is potentially
implicated in the rapid growth and high migratory property
of the tongue SCC.
LncRNA could contribute to the cancer progression
by controlling the process of proliferation and migration
[16, 17]. In view of the association with tumor stages
(OTTHUMG00000002490) and regional nodal status
(OTTHUMT00000048112) of oral tongue patients, we
suggested that lncRNA expression could possibly link to the
progression of tongue squamous cell carcinoma. To explore
the association, we treated the tongue cancer cell line with
chemotherapeutic drugs which target highly proliferating
cell and cell with high migratory potency [18, 19]. Both
OTTHUMG00000002490 and OTTHUMT0000004811
demonstrated significant changes and the expression
changes were responsive to the treatment dosage of 5-Fu
and paclitaxel, revealing that the 2 lncRNAs can modulate
the response of tongue cancer cells to chemotherapeutic
agents. In addition, targeting lncRNA is suggested to be
a feasible approach to overcome the resistance against
chemotherapeutic drugs due to the observation that cancer
cells expressing particular lncRNA are less responsive to
the cytotoxic drugs [20, 21]. For example, in non-small
cell lung cancer, it has been reported that cancer cells with
high lncRNA AK126698 expression are associated with the
cisplatin resistant phenotype [22]. As cisplatin-resistance is
a challenge to the treatment efficacy of tongue squamous
cell carcinoma, we developed a cisplatin-resistant model to
examine the potential implication of the 2 lncRNAs to the
development of resistant phenotype in oral tongue cancers.
The significant changes in OTTHUMG00000002490 and
OTTHUMT0000004811 observed in the resistant cell line
indicated the potential association with the development of
cisplatin resistance in tongue SCC.
5. Conclusions
In conclusion, our results indicated that oncogenic/tumor-
suppressing lncRNA could potentially be identified through
computational exploration of the existing microarray data.
The associations of lncRNA with the clinical features of
tongue SCC patients substantiate the claim that lncRNA
deregulation is linked to the biology activity of tongue SCC.
Whether the deregulated lnRNA could possibly be used as
diagnostic/prognostic indicators has yet to be elucidated.
Further studies are warranted to decipher the functional roles
of lncRNA in the pathogenesis of tongue SCC.
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